Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
Saved in:
| Title: | Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. |
|---|---|
| Authors: | Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Desai P; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York City, NY, USA., Zeidner JF; Department of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Wolach O; Institute of Hematology, Rabin Medical Center, Petah Tikva, Israel., LeBlanc TW; Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Abedin S; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Vachhani P; Division of Hematology/Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Sweet K; Department of Hematological Malignancies, Moffitt Cancer Center, Tampa, FL, USA., Moshe Y; Department of Hematology, Tel Aviv (Sourasky) Medical Center, Tel Aviv, Israel., Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA., Lai C; Department of Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Levitz D; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA., Nachmias B; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel., Mozessohn L; Division of Hematology/Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada., Xavier M; Department of Medical Oncology and Hematology, Scripps Cancer Center, San Diego, CA, USA., Zuckerman T; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Konopleva M; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA., Chen EC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stahl M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Xu Y; AbbVie Inc, North Chicago, IL, USA., Bui CN; AbbVie Inc, North Chicago, IL, USA., Miu K; AbbVie Inc, North Chicago, IL, USA., Schmidt X; AbbVie Inc, North Chicago, IL, USA., Grunspan M; AbbVie Israel, Hod Hasharon, Israel., Lin CW; Genentech, South San Francisco, CA, USA., Ma E; Genentech, South San Francisco, CA, USA., Montez M; Genentech, South San Francisco, CA, USA., Guérin A; Analysis Group, Inc, Montreal, QC, Canada., Burne R; Analysis Group, Inc, Montreal, QC, Canada., Easson K; Analysis Group, Inc, Montreal, QC, Canada., Levesque-Leroux M; Analysis Group, Inc, Montreal, QC, Canada., Baraka E; Analysis Group, Inc, Montreal, QC, Canada., Goldberg AD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2026 Jul 29, pp. 1-13. Date of Electronic Publication: 2026 Jul 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
